MX355102B - Procesos para hacer los inhibidores de la proteasa del hcv. - Google Patents

Procesos para hacer los inhibidores de la proteasa del hcv.

Info

Publication number
MX355102B
MX355102B MX2014008516A MX2014008516A MX355102B MX 355102 B MX355102 B MX 355102B MX 2014008516 A MX2014008516 A MX 2014008516A MX 2014008516 A MX2014008516 A MX 2014008516A MX 355102 B MX355102 B MX 355102B
Authority
MX
Mexico
Prior art keywords
protease inhibitors
processes
hcv protease
making hcv
making
Prior art date
Application number
MX2014008516A
Other languages
English (en)
Other versions
MX2014008516A (es
Inventor
A Lukin Kirill
Original Assignee
Abbvie Ireland Unlimited Co
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbvie Ireland Unlimited Co filed Critical Abbvie Ireland Unlimited Co
Publication of MX2014008516A publication Critical patent/MX2014008516A/es
Publication of MX355102B publication Critical patent/MX355102B/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/14—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing three or more hetero rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/18—Drugs for disorders of the alimentary tract or the digestive system for pancreatic disorders, e.g. pancreatic enzymes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D231/00—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings
    • C07D231/54—Heterocyclic compounds containing 1,2-diazole or hydrogenated 1,2-diazole rings condensed with carbocyclic rings or ring systems
    • C07D231/56—Benzopyrazoles; Hydrogenated benzopyrazoles
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
    • C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
    • C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/06—Dipeptides
    • C07K5/06139—Dipeptides with the first amino acid being heterocyclic
    • C07K5/06165—Dipeptides with the first amino acid being heterocyclic and Pro-amino acid; Derivatives thereof
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K5/00—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof
    • C07K5/04—Peptides containing up to four amino acids in a fully defined sequence; Derivatives thereof containing only normal peptide links
    • C07K5/08—Tripeptides
    • C07K5/0802—Tripeptides with the first amino acid being neutral
    • C07K5/0804—Tripeptides with the first amino acid being neutral and aliphatic
    • C07K5/0808—Tripeptides with the first amino acid being neutral and aliphatic the side chain containing 2 to 4 carbon atoms, e.g. Val, Ile, Leu
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02P—CLIMATE CHANGE MITIGATION TECHNOLOGIES IN THE PRODUCTION OR PROCESSING OF GOODS
    • Y02P20/00—Technologies relating to chemical industry
    • Y02P20/50—Improvements relating to the production of bulk chemicals
    • Y02P20/582—Recycling of unreacted starting or intermediate materials

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Biochemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Virology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • General Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Enzymes And Modification Thereof (AREA)

Abstract

Se describen procesos eficientes para hacer inhibidores de la proteasa del HCV. En una modalidad, el proceso usa nuevos derivados de idazolida de vinilo-ACCA.
MX2014008516A 2012-01-11 2013-01-11 Procesos para hacer los inhibidores de la proteasa del hcv. MX355102B (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201261585280P 2012-01-11 2012-01-11
PCT/US2013/021118 WO2013106631A1 (en) 2012-01-11 2013-01-11 Processes for making hcv protease inhibitors

Publications (2)

Publication Number Publication Date
MX2014008516A MX2014008516A (es) 2014-08-21
MX355102B true MX355102B (es) 2018-04-05

Family

ID=47599178

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2014008516A MX355102B (es) 2012-01-11 2013-01-11 Procesos para hacer los inhibidores de la proteasa del hcv.

Country Status (8)

Country Link
US (1) US9346785B2 (es)
EP (1) EP2802595B1 (es)
JP (1) JP6038179B2 (es)
CN (2) CN107964006A (es)
CA (1) CA2863002A1 (es)
ES (1) ES2563479T3 (es)
MX (1) MX355102B (es)
WO (1) WO2013106631A1 (es)

Family Cites Families (43)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6767991B1 (en) 1997-08-11 2004-07-27 Boehringer Ingelheim (Canada) Ltd. Hepatitis C inhibitor peptides
US6608027B1 (en) 1999-04-06 2003-08-19 Boehringer Ingelheim (Canada) Ltd Macrocyclic peptides active against the hepatitis C virus
US6867185B2 (en) 2001-12-20 2005-03-15 Bristol-Myers Squibb Company Inhibitors of hepatitis C virus
US7119072B2 (en) 2002-01-30 2006-10-10 Boehringer Ingelheim (Canada) Ltd. Macrocyclic peptides active against the hepatitis C virus
US7091184B2 (en) 2002-02-01 2006-08-15 Boehringer Ingelheim International Gmbh Hepatitis C inhibitor tri-peptides
MY140680A (en) 2002-05-20 2010-01-15 Bristol Myers Squibb Co Hepatitis c virus inhibitors
US20040180815A1 (en) 2003-03-07 2004-09-16 Suanne Nakajima Pyridazinonyl macrocyclic hepatitis C serine protease inhibitors
ATE422895T1 (de) 2003-04-16 2009-03-15 Bristol Myers Squibb Co Makrocyclische isochinolinpeptidinhibitoren des hepatitis-c-virus
US7176208B2 (en) 2003-04-18 2007-02-13 Enanta Pharmaceuticals, Inc. Quinoxalinyl macrocyclic hepatitis C serine protease inhibitors
EP1673385B1 (en) 2003-09-22 2011-03-02 Boehringer Ingelheim International GmbH Macrocyclic peptides active against the hepatitis c virus
US7491794B2 (en) 2003-10-14 2009-02-17 Intermune, Inc. Macrocyclic compounds as inhibitors of viral replication
ES2338666T3 (es) 2004-03-15 2010-05-11 Boehringer Ingelheim International Gmbh Procedimiento para la preparacion de dipeptidos macrociclicos adecuados para el tratamiento de infecciones viricas de la hepatitis c.
US7323447B2 (en) * 2005-02-08 2008-01-29 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
WO2006138187A1 (en) * 2005-06-13 2006-12-28 Yong-Qian Wu Enhanced tissue penetration prodrugs
AR057456A1 (es) * 2005-07-20 2007-12-05 Merck & Co Inc Inhibidores de la proteasa ns3 del vhc
EP2305696A3 (en) 2005-07-25 2011-10-12 Intermune, Inc. Macrocyclic inhibitors of Hepatitis C virus replication
JO2768B1 (en) * 2005-07-29 2014-03-15 تيبوتيك فارماسيوتيكالز ليمتد Large cyclic inhibitors of hepatitis C virus
PE20070211A1 (es) 2005-07-29 2007-05-12 Medivir Ab Compuestos macrociclicos como inhibidores del virus de hepatitis c
WO2007130592A2 (en) 2006-05-04 2007-11-15 Crawford Ted C Head cap for a wrench head, wrench and method utilizing the same
US7728148B2 (en) 2006-06-06 2010-06-01 Enanta Pharmaceuticals, Inc. Acyclic oximyl hepatitis C protease inhibitors
US9526769B2 (en) 2006-06-06 2016-12-27 Enanta Pharmaceuticals, Inc. Macrocylic oximyl hepatitis C protease inhibitors
UY30437A1 (es) 2006-06-26 2008-01-31 Enanta Pharm Inc Quinoxalinil macroceclicos inhibidores de serina proteasa del virus de la hepatitis c
WO2008016993A1 (en) * 2006-08-01 2008-02-07 Alcon Research, Ltd. Intermediates and methods for serotonergic agonist synthesis
US7635683B2 (en) 2006-08-04 2009-12-22 Enanta Pharmaceuticals, Inc. Quinoxalinyl tripeptide hepatitis C virus inhibitors
US20120220520A1 (en) 2006-10-17 2012-08-30 Van T Klooster Gerben Albert Eleutherius Bioavailable combinations for hcv treatment
WO2008057208A2 (en) 2006-10-27 2008-05-15 Merck & Co., Inc. Hcv ns3 protease inhibitors
US20080207528A1 (en) 2007-02-01 2008-08-28 Syaulan Yang Hcv protease inhibitors
US20080279821A1 (en) 2007-04-26 2008-11-13 Deqiang Niu Arylpiperidinyl and arylpyrrolidinyl macrocyclic hepatitis c serine protease inhibitors
CN101754974B (zh) 2007-07-19 2016-02-03 Msd意大利有限公司 作为抗病毒剂的大环化合物
US20090111757A1 (en) 2007-10-25 2009-04-30 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
RU2490272C2 (ru) 2008-02-04 2013-08-20 Айденикс Фармасьютикалз, Инк. Макроциклические ингибиторы серинпротеазы
WO2009142842A2 (en) 2008-04-15 2009-11-26 Intermune, Inc. Novel macrocyclic inhibitors of hepatitis c virus replication
US20090285773A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
US20090285774A1 (en) 2008-05-15 2009-11-19 Bristol-Myers Squibb Company Hepatitis C Virus Inhibitors
CN101580535B (zh) 2008-05-16 2012-10-03 太景生物科技股份有限公司 丙型肝炎病毒蛋白酶抑制剂
UY32099A (es) 2008-09-11 2010-04-30 Enanta Pharm Inc Inhibidores macrocíclicos de serina proteasas de hepatitis c
US8044087B2 (en) 2008-09-29 2011-10-25 Bristol-Myers Squibb Company Hepatitis C virus inhibitors
US20110245529A1 (en) 2008-10-10 2011-10-06 Kaneka Corporation Method for producing optically active vinylcyclopropanecarboxylic acid derivative and optically active vinylcyclopropaneamino acid derivative
AR075584A1 (es) 2009-02-27 2011-04-20 Intermune Inc COMPOSICIONES TERAPEUTICAS QUE COMPRENDEN beta-D-2'-DESOXI-2'-FLUORO-2'-C-METILCITIDINA Y UN DERIVADO DE ACIDO ISOINDOL CARBOXILICO Y SUS USOS. COMPUESTO.
TW201040181A (en) 2009-04-08 2010-11-16 Idenix Pharmaceuticals Inc Macrocyclic serine protease inhibitors
LT2421527T (lt) 2009-04-25 2018-09-10 F. Hoffmann-La Roche Ag Farmakokinetinių savybių pagerinimo būdai
EP2477980B1 (en) * 2009-09-15 2016-06-08 Taigen Biotechnology Co., Ltd. Hcv protease inhibitors
US8476225B2 (en) 2009-12-04 2013-07-02 Gilead Sciences, Inc. Antiviral compounds

Also Published As

Publication number Publication date
CA2863002A1 (en) 2013-07-18
CN104136453A (zh) 2014-11-05
MX2014008516A (es) 2014-08-21
CN107964006A (zh) 2018-04-27
EP2802595A1 (en) 2014-11-19
HK1201277A1 (zh) 2015-08-28
ES2563479T3 (es) 2016-03-15
WO2013106631A1 (en) 2013-07-18
JP6038179B2 (ja) 2016-12-07
US9346785B2 (en) 2016-05-24
JP2015508413A (ja) 2015-03-19
CN104136453B (zh) 2018-01-12
US20130178630A1 (en) 2013-07-11
EP2802595B1 (en) 2016-01-06

Similar Documents

Publication Publication Date Title
IL265611A (en) (S2)–N–[S)1)–1–cyano–2–phenylethanyl]–1,4–oxazaphene–2–carboxamides as dipeptidyl peptidase 1 inhibitors
MX2015006324A (es) Metodos para la fabricacion de polipeptidos proteoliticamente procesados.
UY34559A (es) Inhibidores de bromodominios
MY181069A (en) Methods and processes for non-invasive assessment of genetic variations
IN2014DN08481A (es)
PH12015500040B1 (en) Supercritical hydrolysis of biomass
EP3194369A4 (en) Pyrazolyl-substituted pyridone compounds as serine protease inhibitors
UA117565C2 (uk) Модифікований олігонуклеотид
MX370649B (es) Proceso para la preparacion de teneligliptina.
EA027567B9 (ru) Способ приготовления стабильного при хранении напитка
IN2014DN09798A (es)
IN2014MU00455A (es)
MX2015006986A (es) Solucion de trombina y metodos de uso de esta.
IN2013MU01113A (es)
IN2015DN03815A (es)
IN2014DN10209A (es)
IN2014DN11218A (es)
MX2015009565A (es) Proceso para elaborar derivados de magnolol.
MX361888B (es) Un procedimiento mejorado para producir zilpaterol.
IN2014DN10677A (es)
HK1201277A1 (zh) 用於製備hcv蛋白酶抑制劑的方法
GB2491544A (en) Perpetum mobile
UA68756U (uk) Фторовмісні ізомерні бісдіоли, що містять азогрупи, як мономери для поліуретанів
MX2017012348A (es) Procesos e intermedios para preparar un inhibidor macrociclico de proteasa de vhc.
MX2015004411A (es) Compuestos utiles para elaborar inhibidores de proteasa de virus de la hepatitis c (vhc).

Legal Events

Date Code Title Description
GB Transfer or assignment

Owner name: ABBVIE IRELAND UNLIMITED COMPANY

FG Grant or registration